Development of new protein vectors for the physiologic delivery of large therapeutic compounds to the cns

Abstract

The central nervous system (CNS) is a sanctuary protected by several barriers; the major one being the blood–brain barrier (BBB). The BBB is formed by the specifi c nature of the endothelial cells of the brain capillaries only allowing brain access to nutrients necessary for brain cell survival and function. These properties of the BBB result in the incapacity of therapeutic compounds small and large to reach the brain at therapeutic concentrations. Various strategies are now being developed to enhance the amount and concentration of these compounds in the brain parenchyma. The development of new technologies such as peptide vectors will achieve the delivery of active agents in therapeutic concentration across the BBB to treat brain diseases such as cancer or neurodegenerative disorders. New technologies are being developed and will be presented. Critical opinions will be given on these different platforms to point out their advantages and disadvantages.